<DOC>
	<DOCNO>NCT01390519</DOCNO>
	<brief_summary>This Norwegian prospective registration , observational study patient advance renal cell cancer Afinitor treatment failure one Tyrosine Kinase Inhibitor ( TKI ) ( e.g . sunitinib sorafenib ) . The goal document treatment algorithm patient Norway efficacy tolerability AfinitorÂ® pure 2.line setting .</brief_summary>
	<brief_title>A Norwegian Observational Trial Evaluating Treatment Advanced Renal Cell Cancer Patients Under Treatment Afinitor</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age &gt; 18 year Confirmed diagnosis advance renal cell cancer Progression one VEGF TKI ( e.g . sunitibin , sorafenib ) Written inform consent Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>mRCC ,</keyword>
	<keyword>observational ,</keyword>
	<keyword>Afinitor ,</keyword>
	<keyword>everolimus ,</keyword>
	<keyword>2.line</keyword>
</DOC>